The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
The UK High Court has today ruled that the National Health Service (NHS) England can legally provide the game-changing HIV prevention drug, Truvada, as a pre-exposure prophylaxis (PrEP) to HIV negative people most at risk of HIV – but only if it chooses to.
Prevalence of hepatitis C (HCV) among people who inject drugs in Europe is very high – in excess of 50% across six countries in the region and an estimated 84% in Portugal. But a new report released by EU drug body for World Hepatitis Day (July 28), shows that a combination of new treatments and prevention interventions gives significant reason for optimism in curbing the HCV epidemic among drug users in the region.
Pilot study demonstrates that delivering antiretroviral treatment to individuals presenting to emergency departments with suspected acute HIV infection is highly feasible,
An injectable version of the opiate substitution treatment (OST) buprenorphine – which is delivered through an implant – has been approved for use in the USA by the Food and Drug Administration (FDA).
The number of new HIV infections in the USA has fallen by 11% between 2010 and 2015, however the rate of decline falls far short of the goals set in the 2010-2015 National HIV/AIDS Strategy (NHAS).
Cases of antibiotic resistant gonorrhoea are on the rise in England and spreading across the country, according to a statement issued by Public Health England (PHE) on Sunday.
National Health Service (NHS) England has decided against providing pre-exposure prophylaxis (PrEP) for HIV-negative people at a high risk of HIV, sparking outrage among a number of HIV charities and service providers in the UK.